ArticleFrontiers in pharmacology2025
Nanozyme-armored natural enzymes for acute kidney injury management via inflammation regulation and oxidative damage mitigation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advanced nanocatalytic medicine for genitourinary diseases: Reactive oxygen modulation, precision therapeutics, and clinical translation.Materials today. Bio · 2026Article
- Recent advances in stimuli-responsive nanomaterials for the treatment of acute kidney injury.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is a major global disease with a complex pathogenesis and a lack of safe and effective radical treatments. Reactive oxygen species (ROS) and inflammation are key drivers of AKI, making antioxidant and anti_inflammatory strategies promising. This study designed a stable nanozyme to simultaneously scavenge ROS and control inflammation. Methods: Using a biomimetic mineralization approach, catalase (CAT) was immobilized on manganese_based metal sulfide to construct the CAT@MnS nanozyme. Results: Discussion: This study successfully developed a CAT@MnS nanozyme that integrates ROS scavenging with inflammation regulation. The biomimetic mineralization strategy enhanced the stability and therapeutic synergy of the system. The nanozyme offers a new approach for the synergistic treatment of AKI and shows promising potential for translational application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.